Venus Remedies Ltd

NSE
VENUSREM •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Venus Remedies Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
75.09% Gain from 52W Low
18
TTM PE Ratio
Below industry Median
18.2
Price to Book Ratio
Low in industry
1.1
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is much higher than 1
2.5
RSI
RSI is mid-range
65
MFI
MFI Overbought
74.7

Venus Remedies Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Venus Remedies Ltd shareholding Pattern

Promoter
41.8%
Foreign Institutions
1.5%
Domestic Institutions
0.2%
Public
56.6%
Promoter
41.8%
Foreign Institutions
1.6%
Domestic Institutions
0.2%
Public
56.5%
Promoter
41.8%
Foreign Institutions
1%
Domestic Institutions
0.2%
Public
57.1%
Promoter
41.8%
Foreign Institutions
1%
Domestic Institutions
0.2%
Public
57.1%
Promoter
41.8%
Foreign Institutions
1%
Domestic Institutions
0.2%
Public
57.1%
Promoter
41.8%
Foreign Institutions
1.1%
Domestic Institutions
0.2%
Public
57%

Venus Remedies Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
385.80
10Day EMA
380.30
12Day EMA
378.20
20Day EMA
370.10
26Day EMA
364.60
50Day EMA
351.20
100Day EMA
342.80
200Day EMA
326.90
5Day SMA
385.50
10Day SMA
378.50
20Day SMA
375.00
30Day SMA
358.80
50Day SMA
335.90
100Day SMA
335.10
150Day SMA
354.40
200Day SMA
338.50
Delivery & Volume
Resistance & Support
393.22
Pivot
Resistance
First Resistance
401.23
Second Resistance
413.77
Third Resistance
421.78
Support
First Support
380.68
Second support
372.67
Third Support
360.13
Relative Strength Index
65.02
Money Flow Index
74.70
MACD
13.64
MACD Signal
13.35
Average True Range
15.42
Average Directional Index
28.56
Rate of Change (21)
9.69
Rate of Change (125)
-4.45
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Kilitch Drugs(I) Ltd.
544.15
175
470
Ambalal Sarabhai Enterprises Ltd.
-
-
-
Shukra Pharmaceuticals Ltd.
-
-
-
Fredun Pharmaceuticals Ltd.
-
-
-
Kwality Pharmaceuticals Ltd.
-
-
-
Zim Laboratories Ltd.
-
-
-

Venus Remedies Ltd Company background

Founded in: 1989
Managing director: Pawan Chaudhary
Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as WHOGMP as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with USFDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc.In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox3000,Paroxin3000,Pisa3000,Mical,Ronid,Dexolyte and Detox.The year 200506 saw many new milestone achievements by the Company like commercial operation of its most modern and technosavvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, GermanGMP certified pharmaceutical unit at Werne, Germany, launch of its second RD Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well. The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 200607. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the Tobracef brand in 200809. It launched its anticancer drug Docetaxel in Europe by end 2011, launched ACHNIL, the onceaday pain management therapy in India in 2011 launched Cytomib, a firsttime therapy against blood cancer in 2011 launched Taxedol in threestrengths20 mg, 80 mg and 120 mg in 2012.In 2013, the Company established preclinical proof of concept for its Drug ProteinPolymer Conjugate (DPPC) introduced ReadytoUse a Single Vial Taxedol in India launched Trois, a miracle nanoemulsion for arthritic Pain launched Elores CSE 1034, a US patent protected product in India, launched its first OTC product Ezenus. In 2014, the Company launched ELORES, an antibiotic to fight superbugs. In 202122, it launched first product in the consumer healthcare space, R3SET a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decisionmaking, aBI tool like Tableau was also launched in 2022.
Read More

Venus Remedies Ltd FAQs

Venus Remedies Ltd shares are currently priced at 388.7 on NSE and 390.1 on BSE as of 7/11/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Venus Remedies Ltd [VENUSREM] share was 35.62. The Venus Remedies Ltd [VENUSREM] share hit a 1-year low of Rs. 222 and a 1-year high of Rs. 430.

The market cap of Venus Remedies Ltd is Rs. 519.57 Cr. as of 7/11/2024 12:00:00 AM.

The PE ratios of Venus Remedies Ltd is 17.09 as of 7/11/2024 12:00:00 AM.

The PB ratios of Venus Remedies Ltd is 1.02 as of 7/11/2024 12:00:00 AM

You can easily buy Venus Remedies Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -